[
    [
        {
            "time": "2021-07-09",
            "original_text": "恒瑞医药董事长周云曙因身体原因辞职，孙飘扬重新出任董事长。",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "董事长",
                    "周云曙",
                    "辞职",
                    "孙飘扬",
                    "重新出任"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "恒瑞医药董事长周云曙因身体原因辞职，孙飘扬重新出任董事长。",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-07-09",
            "original_text": "恒瑞医药股价半年跌去三分之一，市值蒸发3500亿。",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "股价",
                    "下跌",
                    "市值蒸发"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "恒瑞医药股价半年跌去三分之一，市值蒸发3500亿。",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-07-09",
            "original_text": "大摩下调快手评级至低配，恒瑞医药投资评级恶化。",
            "features": {
                "keywords": [
                    "大摩",
                    "快手",
                    "恒瑞医药",
                    "投资评级",
                    "恶化"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "大摩下调快手评级至低配，恒瑞医药投资评级恶化。",
                "Correlation": 6,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-07-09",
            "original_text": "恒瑞医药获得SHR6508注射液药物临床试验批准通知书。",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "SHR6508",
                    "注射液",
                    "临床试验",
                    "批准"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药获得SHR6508注射液药物临床试验批准通知书。",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-07-09",
            "original_text": "恒瑞医药与万春医药达成14亿元合作，联合开发普那布林。",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "万春医药",
                    "合作",
                    "普那布林"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药与万春医药达成14亿元合作，联合开发普那布林。",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]